This presentation explores the direct impact of my bacterial transcription studies on drug development strategies, focusing on Mycobacterium tuberculosis (Mtb) and SARS-CoV-2. In the context of TB, we dissect pathogen-specific transcriptional mechanisms, emphasizing the initiation and elongation steps of the transcription cycle in Mtb. These insights aim to address the pressing challenges posed by drug-resistant TB and inform targeted drug development.

Transitioning to SARS-CoV-2, I will discuss how nucleotide processing proteins collaborate to replicate and transcribe the viral genome. This exploration contributes valuable insights for developing effective antiviral interventions in the ongoing fight against COVID-19 and future pandemics. The interconnectedness of these studies underscores their collective impact on uncovering new biology, advancing drug development strategies and addressing the challenges posed by the formidable pathogens, TB and SARS-CoV-2.